Literature DB >> 9692032

Glaucoma update: epidemiology and new approaches to medical management.

J G Flanagan1.   

Abstract

Glaucoma describes a group of ocular conditions which involve progressive optic nerve damage associated with loss of visual function and, frequently, with elevated intraocular pressure. Recent estimates of worldwide prevalence predict that 67 million people will suffer from glaucoma by the year 2000. Although the clinical features of glaucoma are reasonably well described, the pathogenesis of optic nerve damage remains unclear. Intraocular pressure (IOP) is accepted as an important risk factor; however, it is clear that other factors play a role in the pathogenesis of the disease, and such factors may interact with IOP to greatly enhance its harmful effects. Many of the new therapeutic approaches to the stabilisation and potential cure of glaucoma attempt to address these non-IOP factors. The aim of the following paper is to consider the implications of new estimates of disease prevalence, discuss theories related to optic nerve damage and outline new and future approaches to the medical management of the disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9692032

Source DB:  PubMed          Journal:  Ophthalmic Physiol Opt        ISSN: 0275-5408            Impact factor:   3.117


  3 in total

1.  Metabolic vulnerability disposes retinal ganglion cell axons to dysfunction in a model of glaucomatous degeneration.

Authors:  Selva Baltan; Denise M Inman; Camelia A Danilov; Richard S Morrison; David J Calkins; Philip J Horner
Journal:  J Neurosci       Date:  2010-04-21       Impact factor: 6.167

2.  Elevated pressure downregulates ZO-1 expression and disrupts cytoskeleton and focal adhesion in human trabecular meshwork cells.

Authors:  Xuejiao Yang; Bingqian Liu; Yujing Bai; Min Chen; Yiqing Li; Mengfei Chen; Yantao Wei; Jian Ge; Yehong Zhuo
Journal:  Mol Vis       Date:  2011-11-16       Impact factor: 2.367

3.  Hybrid formulations of liposomes and bioadhesive polymers improve the hypotensive effect of the melatonin analogue 5-MCA-NAT in rabbit eyes.

Authors:  Daniela Quinteros; Marta Vicario-de-la-Torre; Vanessa Andrés-Guerrero; Santiago Palma; Daniel Allemandi; Rocío Herrero-Vanrell; Irene T Molina-Martínez
Journal:  PLoS One       Date:  2014-10-20       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.